Avoro Capital Advisors LLC - Q1 2022 holdings

$5.48 Billion is the total value of Avoro Capital Advisors LLC's 43 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 20.0% .

 Value Shares↓ Weighting
APLS BuyAPELLIS PHARMACEUTICALS INC$480,155,000
+18.7%
9,450,000
+10.5%
8.77%
+27.3%
MRTX BuyMIRATI THERAPEUTICS INC$437,822,000
-41.2%
5,325,000
+4.9%
7.99%
-36.9%
ARGX BuyARGENX SEsponsored adr$395,714,000
+17.1%
1,255,000
+30.1%
7.22%
+25.6%
XBI BuySPDR SERIES TRUST - S&P BIOTECHetf$274,134,000
+133.2%
3,050,000
+190.5%
5.00%
+150.1%
ASND BuyASCENDIS PHARMAsponsored adr$258,192,000
-4.0%
2,200,000
+10.0%
4.71%
+2.9%
SRPT BuySAREPTA THERAPEUTICS INC$244,906,000
-13.0%
3,135,000
+0.3%
4.47%
-6.6%
BMRN BuyBIOMARIN PHARMACEUTICAL INC$233,999,000
-5.4%
3,035,000
+8.4%
4.27%
+1.5%
ALNY BuyALNYLAM PHARMACEUTICALS INC$212,277,000
+16.4%
1,300,000
+20.9%
3.88%
+24.9%
FOLD BuyAMICUS THERAPEUTICS INC$194,135,000
-9.1%
20,500,000
+10.8%
3.54%
-2.6%
SGEN NewSEAGEN INC$189,426,0001,315,000
+100.0%
3.46%
IOVA BuyIOVANCE BIOTHERAPEUTICS INC$151,931,000
-8.3%
9,125,000
+5.2%
2.77%
-1.6%
KURA BuyKURA ONCOLOGY INC$77,184,000
+37.8%
4,800,000
+20.0%
1.41%
+47.8%
KRYS BuyKRYSTAL BIOTECH INC$66,873,000
+101.3%
1,005,000
+111.6%
1.22%
+116.1%
ACAD BuyACADIA PHARMACEUTICALS INC$55,101,000
+7.3%
2,275,000
+3.4%
1.01%
+15.1%
PMVP BuyPMV PHARMACEUTICALS INC$45,804,000
+35.3%
2,200,000
+50.2%
0.84%
+45.1%
SNDX BuySYNDAX PHARMACEUTICALS INC$38,592,000
-18.9%
2,220,500
+2.1%
0.70%
-13.0%
DSGN BuyDESIGN THERAPEUTICS INC$35,889,000
+2.5%
2,222,222
+35.8%
0.66%
+9.9%
KYMR BuyKYMERA THERAPEUTICS INC$34,554,000
-1.0%
816,500
+48.5%
0.63%
+6.2%
BCRX NewBIOCRYST PHARMACEUTICLAS INC$30,488,0001,875,000
+100.0%
0.56%
RNA BuyAVIDITY BIOSCIENCES INC$24,011,000
-17.9%
1,300,000
+5.7%
0.44%
-12.0%
PRAX BuyPRAXIS PRECISION MEDICINES INC$21,952,000
-37.4%
2,150,000
+20.8%
0.40%
-32.8%
BuyDICE THERAPEUTICS INC$20,565,000
+44.4%
1,075,000
+91.1%
0.38%
+55.0%
RARE NewULTRAGENYX PHARMACEUTICAL INC$16,703,000230,000
+100.0%
0.30%
AMTI NewAPPLIED MOLECULAR TRANS INC$7,746,0001,030,000
+100.0%
0.14%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-05-16
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
AMICUS THERAPEUTICS INC36Q3 202317.9%
MIRATI THERAPEUTICS INC.35Q3 202317.2%
BIOMARIN PHARMACEUTICAL INC31Q3 20238.0%
SAREPTA THERAPUTICS INC28Q3 202314.8%
ASCENDIS PHARMA28Q3 20239.1%
ARGENX SE26Q3 20239.5%
IOVANCE BIOTHERAPEUTICS INC26Q3 20239.1%
FENNEC PHARMACEUTICALS INC25Q3 20230.4%
MADRIGAL PHARMACEUTICALS INC22Q3 20237.2%
XENON PHARMACEUTICALS INC22Q3 20233.3%

View Avoro Capital Advisors LLC's complete holdings history.

Latest significant ownerships (13-D/G)
Avoro Capital Advisors LLC Q1 2022 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Adverum Biotechnologies, Inc.Sold outFebruary 14, 202300.0%
DICE Therapeutics, Inc.February 14, 20232,525,5555.3%
IOVANCE BIOTHERAPEUTICS, INC.February 14, 20237,020,0004.4%
IVERIC bio, Inc.February 14, 20236,750,0005.0%
Kura Oncology, Inc.February 14, 20233,105,0004.5%
Aadi Bioscience, Inc.September 26, 20222,849,40211.7%
ARENA PHARMACEUTICALS INCFebruary 11, 20221,235,0002.0%
AVADEL PHARMACEUTICALS PLCFebruary 11, 20221,670,0002.9%
FENNEC PHARMACEUTICALS INC.February 11, 20221,200,0004.6%
POINT Biopharma Global Inc.Sold outFebruary 11, 202200.0%

View Avoro Capital Advisors LLC's complete significant-ownership history.

Latest filings
TypeFiled
42024-06-14
13F-HR2024-05-15
SC 13G/A2024-04-23
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Avoro Capital Advisors LLC's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported total value is incorrect (5477562000.0 != 5477565000.0)

Export Avoro Capital Advisors LLC's holdings